Scope & Claims Analysis of US Patent 11,759,440 (Fenfluramine + Stiripentol for Seizure Reduction)
US 11,759,440 is centered on a treatment method that couples (i) fenfluramine dosing and formulation modality (liquid) with (ii) stiripentol co-administration at defined mg/kg/day ranges, using a stated PK/biochemical mechanism: downmodulation of norfenfluramine formation, producing higher fenfluramine levels. Claim coverage fans out across refractory epilepsy subtypes (including Dravet) and co-therapy add-ons, with additional dependent claims that tighten dose reduction percentages and upper-dose cutoffs for fenfluramine when stiripentol is present.
What does US 11,759,440 claim for fenfluramine + stiripentol seizure reduction?
1) What is the core claim concept in US 11,759,440?
Independent claim 1 frames the invention as a method of reducing or ameliorating seizures by administering:
- fenfluramine, and
- stiripentol,
with the functional/mechanistic linkage: “thereby modulating down formation of norfenfluramine, and resulting in higher levels of fenfluramine.”
This claim does not specify dose ranges, patient weight-based amounts, or “liquid formulation” in claim 1 based on the claim set provided. It also does not limit to any epilepsy subtype in claim 1.
2) How do the dependent claims narrow patient population?
Claims 2 and 3 narrow patient diagnosis:
- Claim 2: Dravet syndrome.
- Claim 3: “refractory epilepsy” limited to Dravet, Lennox-Gastaut, Doose (myoclonic-astatic epilepsy), and West syndrome.
This creates explicit coverage for both a single-label population (Dravet) and a small refractory-epilepsy basket.
3) How do co-therapeutic add-on claims broaden method-of-use coverage?
Claim 4 adds an additional layer: “further comprising co-administering… an effective amount of a co-therapeutic agent” selected from a long list (benzodiazepines, barbiturates/antiepileptics, sodium valproate, carbamazepine-family agents, levetiracetam-adjacent entries, cannabidiol, and others), including pharmaceutically acceptable salts.
From a landscape perspective, this claim can materially affect:
- combination-therapy litigation positioning (design-around becomes harder if the product is co-prescribed with standard-of-care antiepileptics), and
- generic/label-carveout strategies (because the claim is written as “further comprising” co-administration, not “exclusive of” co-therapy).
4) What is the second major claim track in US 11,759,440 (liquid fenfluramine + liquid stiripentol dose ranges)?
Claims 5 through 10 introduce a more concrete formulation and dosing architecture:
- Claim 5: liquid fenfluramine at 0.2 to 0.8 mg/kg/day plus liquid stiripentol about 20 to 50 mg/kg/day, yielding the norfenfluramine downmodulation and higher fenfluramine levels.
This track is materially narrower than claim 1 but more enforceable because it ties:
- administration form (“liquid formulation”), and
- dosing windows.
5) How do percentage dose-reduction dependents tighten fenfluramine scope when stiripentol is co-administered?
Claims 6–8 add explicit fenfluramine dose reductions attributable to stiripentol:
- Claim 6: fenfluramine administered at “30% less” than an effective amount in the 0.2 to 0.8 mg/kg/day range due to stiripentol dosing (20–50 mg/kg/day liquid).
- Claim 7: fenfluramine at “50% less than an effective dose of 0.8 mg/kg/day.”
- Claim 8: fenfluramine at “0.56 mg/kg/day or less” (again within the framework of claim 6).
These claims are operationally significant: they define “how much less” and/or “how low” fenfluramine can be, while the method still “reduces or ameliorates seizures.”
6) Are the lower-dose liquid combination claims specific to Dravet?
Yes. Claims 9 and 10 recreate the liquid dosing architecture but limit to Dravet syndrome:
- Claim 9: fenfluramine liquid 0.2–0.8 mg/kg/day + stiripentol liquid ~20–50 mg/kg/day with the norfenfluramine mechanism.
- Claim 10: fenfluramine liquid “40% less” than effective within 0.2–0.8 mg/kg/day due to stiripentol (20–50 mg/kg/day liquid).
How broad is the patent scope: method-of-treatment, patient diagnosis, and regimen constraints?
Breadth assessment by claim elements (based on the claim text provided)
| Claim cluster |
Key limitations |
Practical scope impact |
| Claim 1 |
Fenfluramine + stiripentol; mechanistic/PK-functional outcome (↓ norfenfluramine formation; ↑ fenfluramine levels) |
Broad on patient population and dose/form, but still requires showing the mechanistic outcome in the claim’s terms. |
| Claims 2–4 |
Adds diagnosis (Dravet; or refractory basket) and/or co-therapeutic agents list |
Narrows beneficiaries but expands enforceability for routine adjunct regimens. |
| Claims 5–6 |
Adds liquid formulation requirement and mg/kg/day ranges for both drugs |
Stronger operational hook for infringement analysis; easier to map to actual product labels/prescribing practices. |
| Claims 7–8 |
Adds explicit fenfluramine dose reductions/ceiling |
Reduces design-around by enforcing lower-dose specific targets when stiripentol is used. |
| Claims 9–10 |
Adds Dravet-specific variant with same liquid dosing (and 40% reduction) |
Directly targets a high-value patient segment (Dravet). |
What makes the mechanism clause important for claim construction?
The claims use a “whereby/thereby” style functional linkage: “modulating down formation of norfenfluramine… resulting in higher levels of fenfluramine.” That can matter in litigation and validity by:
- creating an internal nexus between regimen and observed biochemical/PK effect, and
- shaping the evidentiary record needed for infringement (e.g., demonstrating that co-administering stiripentol with fenfluramine under the claimed conditions produces the claimed norfenfluramine suppression and fenfluramine level increase).
Which prior art likely matters for US 11,759,440 and how does the claim language position against it?
Key patentability pressure points inherent in the claim set
Even without the full specification, the claim language points to three classic validity risks in this type of regimen patent:
- Known combination regimens
Fenfluramine and stiripentol are both established antiepileptic agents. Prior art that discloses co-administration for seizure control can challenge novelty unless the prior art also teaches the specific mechanistic PK effect (or the dose/formulation constraints).
- PK interaction teaching
The mechanism clause is explicit: ↓ norfenfluramine formation, ↑ fenfluramine levels. If prior art already describes a metabolic interaction (e.g., stiripentol altering fenfluramine metabolism), then novelty can fail unless the claimed regimen differs (dose ranges, liquid formulation requirement, or specific reduction percentages).
- Dose-range obviousness
Claims 5–8 and 10 heavily depend on dose windows and percentage reductions. Prior art showing effective fenfluramine dosing ranges and known stiripentol co-therapy could drive obviousness arguments for selecting the claimed windows.
Where the claim language creates defensibility
The strongest differentiators embedded in the claim set are:
- liquid formulation requirement for both fenfluramine and stiripentol in claims 5, 6, 9, 10, and by dependency structure in 7–8, and
- specific mg/kg/day ranges (fenfluramine 0.2–0.8 mg/kg/day; stiripentol ~20–50 mg/kg/day), and
- explicit percentage reductions (30%, 40%, 50% relative to defined effective doses/ceilings).
Those elements are the usual anchors against “general combination” prior art.
Patent landscape: how to think about enforceability and freedom-to-operate around US 11,759,440
1) Likely infringement mapping categories
US 11,759,440 creates infringement pathways through at least three real-world execution patterns:
-
Direct co-administration with mechanistic effect
Claim 1 can be implicated by any regimen where fenfluramine and stiripentol are administered together in a way that results in decreased norfenfluramine formation and increased fenfluramine levels, even absent explicit dosing/formulation limitations in the claim text provided.
-
Label/practice match with liquid formulations and dosing windows
Claims 5 and 9 are highly “chartable.” If the clinic uses liquid fenfluramine and liquid stiripentol within those weight-based ranges and observes seizure reduction, infringement analysis becomes regimen-to-regimen.
-
Dose-reduction prescribing under stiripentol co-use
Claims 6–8 and 10 are structured to catch prescribers who reduce fenfluramine dose because stiripentol is added (30%, 40%, 50% reductions; and ≤0.56 mg/kg/day ceiling).
2) Design-around levers implied by the claim set
Based strictly on claim limitations described:
- Avoid the liquid formulation requirement (claims 5, 6, 9, 10).
- Avoid the stiripentol liquid 20–50 mg/kg/day window.
- Avoid the fenfluramine dose windows and/or dose reduction percentages/cutoffs.
- Inhibit the mechanistic nexus (a difficult design-around in practice because the mechanism clause is functional and could be proven empirically).
Regulatory and commercial context: how labeling and prescribing interact with these claims
Orange Book status and FDA pathway relevance
A precise Orange Book and FDA regulatory status analysis requires the Orange Book listing(s) and the patent-to-product mapping (listed drug, NDA number, expiration date, listed use codes). The claim text alone does not provide:
- the listed drug(s) associated with US 11,759,440,
- whether it is tied to an NDA/BLA,
- any listed use codes,
- or whether the patent is listed as covering drug substance, drug product, or method of use.
Because that mapping is not provided here, exclusivity and generic-risk timing cannot be stated from the claim set alone.
Dravet revenue exposure tie-in
Claims 2 and 9–10 focus on Dravet syndrome, which is a high-value niche. From a business perspective, the most likely practical enforcement zone is where fenfluramine is used in combination with stiripentol and clinicians alter fenfluramine dose downward due to the stiripentol interaction.
What generic entry risks exist for fenfluramine + stiripentol methods under this patent?
Risk mechanism
A generic entrant typically faces two different risk channels:
- Product sameness risk
If the generic matches the active ingredients but not the method/regimen, only method claims are impacted in theory.
- Method-of-use infringement risk
If clinicians prescribe the generic fenfluramine in a regimen that meets the method claims (including liquid dosing windows and stiripentol co-administration), then method claims can create exposure even if product formulations differ.
Why claim 4 matters for real-world co-prescribing
If a branded prescriber practice typically includes standard-of-care antiepileptics from claim 4’s list, that can tighten the infringement net for method-of-use claims even if the defendant tries to argue about “standard polytherapy.”
How strong is the patent estate: US 11,759,440’s role relative to other patents in fenfluramine combinations?
A full “estate strength” analysis requires:
- the complete US family (continuations/divisionals),
- parallel jurisdictions (EP/WO/JP, etc.), and
- the full set of related patents in the fenfluramine + stiripentol space.
The claim set provided is sufficient to analyze scope of US 11,759,440 itself, but not enough to quantify estate depth or overlap.
Timeline and expiration: when does US 11,759,440 lose exclusivity?
A specific expiration calculation depends on:
- priority date(s),
- filing date(s),
- and any patent term adjustments or extensions (including for method-of-use patents tied to FDA review timelines).
Those data are not included here, so exclusivity and enforcement end dates cannot be stated.
Key Takeaways
- US 11,759,440 is a seizure-reduction method that couples fenfluramine with stiripentol and ties the regimen to a PK/metabolic outcome: decreased norfenfluramine formation and increased fenfluramine levels.
- Claim scope spans (i) broad combination method framing in claim 1, (ii) diagnosis-limited embodiments (Dravet; and refractory epilepsy basket), and (iii) tightly specified liquid formulation + weight-based dosing windows (fenfluramine 0.2–0.8 mg/kg/day; stiripentol ~20–50 mg/kg/day).
- Dependent claims 6–8 and 10 focus on fenfluramine dose reduction percentages and ceilings when stiripentol is co-administered, creating a practical infringement hook against regimens that lower fenfluramine dose due to the interaction.
- Claim 4 broadens real-world coverage by covering “further comprising” co-therapy with a large list of common antiepileptics, which reduces easy design-around through omission of standard concomitant therapies.
FAQs
-
Does US 11,759,440 require liquid formulations of both drugs to infringe?
Not for claim 1. Claims 5 and 9 explicitly require liquid formulations for both fenfluramine and stiripentol; other claims depend on the liquid claim structure.
-
What fenfluramine dose range is claimed when stiripentol is co-administered?
0.2 mg/kg/day to 0.8 mg/kg/day (liquid fenfluramine), with stiripentol liquid about 20 mg/kg/day to about 50 mg/kg/day (claims 5 and 9).
-
What “dose reduction” embodiments are covered?
Fenfluramine at 30% less than an effective dose within 0.2–0.8 mg/kg/day (claim 6), 50% less than an effective dose of 0.8 mg/kg/day (claim 7), 0.56 mg/kg/day or less (claim 8), and 40% less within 0.2–0.8 mg/kg/day in Dravet embodiments (claim 10).
-
Which epilepsy diagnoses are explicitly included?
Dravet syndrome (claims 2, 9, 10) and refractory epilepsy limited to Dravet, Lennox-Gastaut, Doose syndrome, and West syndrome (claim 3).
-
Does the patent cover seizure reduction with additional standard antiepileptics?
Yes. Claim 4 recites “further comprising” co-administration of an extensive set of co-therapeutic agents, including many benzodiazepines and other antiepileptics.
References (APA)
- United States Patent 11,759,440.
